[1]李菡旖.顺铂同步放化疗方案治疗中晚期宫颈癌的疗效[J].医学信息,2019,32(24):103-104.[doi:10.3969/j.issn.1006-1959.2019.24.034]
 LI Han-yi.Efficacy of Cisplatin Concurrent Chemoradiotherapy for Advanced Cervical Cancer[J].Medical Information,2019,32(24):103-104.[doi:10.3969/j.issn.1006-1959.2019.24.034]
点击复制

顺铂同步放化疗方案治疗中晚期宫颈癌的疗效()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
32卷
期数:
2019年24期
页码:
103-104
栏目:
临床研究
出版日期:
2019-12-15

文章信息/Info

Title:
Efficacy of Cisplatin Concurrent Chemoradiotherapy for Advanced Cervical Cancer
文章编号:
1006-1959(2019)24-0103-02
作者:
李菡旖
(萍乡市赣西肿瘤医院妇科,江西 萍乡 337000)
Author(s):
LI Han-yi
(Department of Gynecology,Ganxi Cancer Hospital,Pingxiang 337000,Jiangxi,China)
关键词:
顺铂放化疗中晚期宫颈癌
Keywords:
CisplatinChemoradiotherapyAdvanced cervical cancer
分类号:
R737.33
DOI:
10.3969/j.issn.1006-1959.2019.24.034
文献标志码:
A
摘要:
目的 探讨顺铂同步放化疗方案治疗中晚期宫颈癌的临床疗效。方法 回顾分析2016年10月~2019年5月于我院就诊的50例中晚期宫颈癌患者的临床资料,随机分为对照组和实验组,各25例。实验组行顺铂同步放化疗方案,对照组行单纯放疗,比较两组近期效果、不良反应及肿瘤标志物含量。结果 实验组肿瘤控制率为84.00%,高于对照组的52.00%,差异有统计学意义(P<0.05);实验组糖类抗原50(CA50)、癌胚抗原(CEA)、鳞状上皮细胞癌相关抗原(SCC)水平均低于对照组,差异有统计学意义(P<0.05);实验组不良反应发生率为40.00%,高于对照组的32.00%,但差异无统计学意义(P>0.05)。结论 顺铂同步放化疗方案治疗中晚期宫颈癌近期疗效较好,有助于降低肿瘤恶性程度,且不增加不良反应,安全性高。
Abstract:
Objective To investigate the clinical efficacy of cisplatin concurrent chemoradiotherapy in the treatment of advanced cervical cancer. Methods The clinical data of 50 patients with advanced cervical cancer who were treated in our hospital from October 2016 to May 2019 were retrospectively analyzed. They were randomly divided into a control group and an experimental group, each with 25 cases. The experimental group received cisplatin concurrent chemoradiotherapy, and the control group received radiotherapy alone. The two groups’ recent effects, adverse reactions, and tumor marker levels were compared.Results The tumor control rate in the experimental group was 84.00%, which was higher than 52.00% in the control group, the difference was statistically significant (P<0.05). The carbohydrate antigen 50 (CA50), carcinoembryonic antigen (CEA), and squamous epithelial cells in the experimental group the level of cancer-associated antigen (SCC) was lower than that in the control group,the difference was statistically significant (P<0.05); the incidence of adverse reactions in the experimental group was 40.00%, which was higher than 32.00% in the control group, but the difference was not statistically significant (P>0.05). Conclusion The cisplatin concurrent chemoradiotherapy regimen has good short-term efficacy in the treatment of advanced cervical cancer. It is helpful to reduce the malignancy of the tumor without increasing adverse reactions and has high safety.

参考文献/References:

[1]童武松,王松林,潘金华.顺铂联合紫杉醇同步放化疗对中晚期宫颈癌患者免疫功能及血清CY-FRA21-1、SCC-Ag的影响[J].海南医学院学报,2016,22(23):2866-2868.[2]王芳芳,廖思辉,陈运强,等.不同化疗药物联合同期放疗治疗局部中晚期宫颈癌的临床疗效及不良反应观察[J].广西医科大学学报,2019,36(3):412-415.[3]Hakim A,Ghoshal S,Verma R,et al.Comparison of Functional Organ Preservation by Concomitant Boost Radiotherapy Versus Concurrent Chemoradiation in Locally Advanced Carcinoma of Larynx or Hypopharynx:A Prospective Randomized Study[J].Indian J Otolaryngol Head Neck Surg,2019,71(3):360-366.[4]张萍,艾斌.实体瘤免疫治疗疗效评价标准[J].国际肿瘤学杂志,2016,43(11):848-851.[5]赵肖丽,周伟慢,王华,等.伊立替康联合顺铂同步放化疗治疗晚期宫颈癌的临床价值及毒副反应分析[J].解放军医药杂志,2019,31(8):30-33.

相似文献/References:

[1]刘贤丰,李子俊.恩度联合培美曲塞与顺铂治疗晚期肺腺癌的临床效果观察[J].医学信息,2019,32(03):148.[doi:10.3969/j.issn.1006-1959.2019.03.048]
 LIU Xian-feng,LI Zi-jun.Clinical Observation of Endo Combined with Pemetrexed and Cisplatin in the Treatment of Advanced Lung Adenocarcinoma[J].Medical Information,2019,32(24):148.[doi:10.3969/j.issn.1006-1959.2019.03.048]
[2]刘 贝,郑 慧,周 旺,等.3D-STI联合心脏综合指数评价肺癌患者GP化疗方案的隐匿性心肌毒性[J].医学信息,2019,32(08):100.[doi:10.3969/j.issn.1006-1959.2019.08.029]
 LIU Bei,ZHENG Hui,ZHOU Wang,et al.Evaluation of Occult Myocardial Toxicity in GP Chemotherapy Regimen of Lung Cancer Patients by 3D-STI Combined with Cardiac Comprehensive Index[J].Medical Information,2019,32(24):100.[doi:10.3969/j.issn.1006-1959.2019.08.029]
[3]张秀芳,陈 萍.安罗替尼联合顺铂治疗晚期卵巢癌恶性腹腔积液的疗效观察[J].医学信息,2019,32(18):132.[doi:10.3969/j.issn.1006-1959.2019.18.044]
 ZHANG Xiu-fang,CHEN Ping.Efficacy of Erlotinib Combined with Cisplatin in the Treatment of Advanced Ovarian Cancer with Malignant Ascites[J].Medical Information,2019,32(24):132.[doi:10.3969/j.issn.1006-1959.2019.18.044]
[4]任勇军,闵旭立,徐 浩,等.洛铂联合表柔比星化疗栓塞治疗原发性肝细胞癌的疗效[J].医学信息,2019,32(24):43.[doi:10.3969/j.issn.1006-1959.2019.24.014]
 REN Yong-jun,MIN Xu-li,XU Hao,et al.Efficacy of Loplatin Combined with Epirubicin Chemotherapy and Embolization for Primary Hepatocellular Carcinoma[J].Medical Information,2019,32(24):43.[doi:10.3969/j.issn.1006-1959.2019.24.014]
[5]李 博.紫杉醇加顺铂治疗晚期老年非小细胞癌的疗效[J].医学信息,2020,33(10):153.[doi:10.3969/j.issn.1006-1959.2020.10.045]
 LI Bo.Paclitaxel Plus Cisplatin in the Treatment of Advanced Elderly Non-small Cell Carcinoma[J].Medical Information,2020,33(24):153.[doi:10.3969/j.issn.1006-1959.2020.10.045]
[6]文 龙,张 彬.食管癌的治疗现状及趋势分析[J].医学信息,2022,35(18):165.[doi:10.3969/j.issn.1006-1959.2022.18.046]
 WEN Long,ZHANG Bin.Treatment Status and Trend Analysis of Esophageal Cancer[J].Medical Information,2022,35(24):165.[doi:10.3969/j.issn.1006-1959.2022.18.046]
[7]王宇鹏,杜学明.上腔静脉压迫综合征的放化疗治疗[J].医学信息,2022,35(21):163.[doi:10.3969/j.issn.1006-1959.2022.21.044]
 WANG Yu-peng,DU Xue-ming.Chemoradiotherapy for Superior Vena Cava Compression Syndrome[J].Medical Information,2022,35(24):163.[doi:10.3969/j.issn.1006-1959.2022.21.044]
[8]苏 凝,樊利萍,秦丽丽,等.恩度联合顺铂胸腔内灌注治疗非小细胞肺癌恶性胸腔积液的疗效[J].医学信息,2021,34(11):155.[doi:10.3969/j.issn.1006-1959.2021.11.043]
 SU Ning,FAN Li-ping,QIN Li-li,et al.Efficacy of Endu Combined with Cisplatin Intrapleural Perfusion in the Treatment of Non-small Cell Lung Cancer with Malignant Pleural Effusion[J].Medical Information,2021,34(24):155.[doi:10.3969/j.issn.1006-1959.2021.11.043]
[9]何显阳,刘方文,黄云英,等.多西他赛联合顺铂新辅助化疗对非小细胞肺癌治疗中相关肿瘤标记物的影响[J].医学信息,2021,34(23):165.[doi:10.3969/j.issn.1006-1959.2021.23.050]
 HE Xian-yang,LIU Fang-wen,HUANG Yun-ying,et al.Effect of Docetaxel Combined with Cisplatin Neoadjuvant Chemotherapy on Related Tumor Markers in the Treatment of Non-small Cell Lung Cancer[J].Medical Information,2021,34(24):165.[doi:10.3969/j.issn.1006-1959.2021.23.050]
[10]张书林,黄盛源,刘忠林,等.吉西他滨和多西他赛联合顺铂治疗晚期非小细胞肺鳞癌的效果比较[J].医学信息,2021,34(24):141.[doi:10.3969/j.issn.1006-1959.2021.24.036]
 ZHANG Shu-lin,HUANG Sheng-yuan,LIU Zhong-lin,et al.Comparison of Gemcitabine and Docetaxel Combined with Cisplatin in the Treatment of Advanced Non-small Cell Lung Squamous Cell Carcinoma[J].Medical Information,2021,34(24):141.[doi:10.3969/j.issn.1006-1959.2021.24.036]

更新日期/Last Update: 2019-12-15